Nurix Therapeutics, Inc. (NRIX) Misses Q3 EPS by 20c

Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($1.03), $0.20 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $7.89 million versus the consensus estimate of $16.05 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c